Waanders G A, Rimoldi D, Liénard D, Carrel S, Lejeune F, Dietrich P Y, Cerottini J C, Romero P
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, CH-1066 Epalinges, Switzerland.
Clin Cancer Res. 1997 May;3(5):685-96.
The expression by melanomas of multiple antigens that are recognized by specific MHC class I-restricted CTLs has been clearly demonstrated. The goal of many immunotherapy protocols being developed is, therefore, the induction and/or augmentation of CTLs specific for such antigens. One approach has been to immunize using irradiated autologous melanoma cells. Responses to this type of immunization and others are often subsequently measured by delayed-type hypersensitivity (DTH) reactions. The aim of this work was to characterize whether specific CTL responses occur at such DTH sites. Cutaneous DTH reactions were observed following injection of irradiated autologous melanoma cells expressing known tumor antigens. We isolated lymphocytes from biopsies of DTH reaction sites and could measure melanoma-specific CTL activity after 2-3 weeks of culture. The T-cell receptor-Vbeta repertoire of the cultured lymphocytes, assessed by flow cytometry, was highly skewed in both the CD4(+) and CD8(+) T-cell subsets. The repertoires were different among cultures derived from independent biopsies of simultaneous or subsequent DTH reaction sites and very different to that of fresh peripheral blood lymphocytes (PBLs) or PBLs cultured under the same conditions. No particular T-cell expansions dominated several DTH reaction sites, nor could they be detected in PBLs. It appears that T-cell responses to this type of immunization may be limited to the local microenvironment. Establishing the value of DTH reactions in determining levels of systemic antitumor immunity requires further investigation; however, such reactions may indicate a patient's competence to mount an antitumor immune response and enable the isolation of tumor-specific CTLs for use in tumor antigen identification.
黑色素瘤对多种可被特定MHC I类限制性细胞毒性T淋巴细胞(CTL)识别的抗原的表达已得到明确证实。因此,许多正在研发的免疫治疗方案的目标是诱导和/或增强针对此类抗原的特异性CTL。一种方法是使用经辐照的自体黑色素瘤细胞进行免疫。对这种免疫方式及其他免疫方式的反应通常随后通过迟发型超敏反应(DTH)来测定。这项工作的目的是确定在这种DTH部位是否发生特异性CTL反应。在注射表达已知肿瘤抗原的经辐照自体黑色素瘤细胞后观察到皮肤DTH反应。我们从DTH反应部位的活检组织中分离淋巴细胞,并在培养2 - 3周后测量黑色素瘤特异性CTL活性。通过流式细胞术评估培养淋巴细胞的T细胞受体Vβ谱,发现CD4(+)和CD8(+) T细胞亚群均高度偏斜。来自同时或随后DTH反应部位独立活检组织的培养物中的谱与新鲜外周血淋巴细胞(PBL)或在相同条件下培养的PBL的谱非常不同。没有特定的T细胞扩增在几个DTH反应部位占主导,在PBL中也检测不到。似乎T细胞对这种免疫方式的反应可能局限于局部微环境。确定DTH反应在确定全身抗肿瘤免疫水平方面的价值需要进一步研究;然而,此类反应可能表明患者产生抗肿瘤免疫反应的能力,并能够分离出用于肿瘤抗原鉴定的肿瘤特异性CTL。